Ipsen Regulated Information | Investor Relations
Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 166 Regulated Information

13 June 2023

13 June 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023

09 June 2023

09 June 2023

Download Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

06 June 2023

06 June 2023

Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
IPSEN – Buy-back programme – Art 5 of MAR – Week 22 – 2023

01 June 2023

01 June 2023

Download Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan

Ipsen – Initiation of the share repurchase program – 1st June 2023 Download (130.74 KB)


01 June 2023

01 June 2023

Download Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023

Ipsen Press Release post SM 31 May 2023 Download (158.73 KB)


1 … 22 23 24 25 26 27 28 … 34

IPN price

€164.50

 €0.60 (0.37%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue